166.21 USD
+0.55 (+0.33%)
166.21 USD
0 (0%)
Overall RGEN gets a fundamental rating of 5 out of 10. We evaluated RGEN against 57 industry peers in the Life Sciences Tools & Services industry. RGEN has an excellent financial health rating, but there are some minor concerns on its profitability. RGEN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RGEN had positive earnings in the past year.
RGEN had a positive operating cash flow in the past year.
RGEN had positive earnings in 4 of the past 5 years.
In the past 5 years RGEN always reported a positive cash flow from operatings.
1.2 Ratios
RGEN has a better Return On Assets (0.06%) than 68.42% of its industry peers.
The Return On Equity of RGEN (0.08%) is better than 70.18% of its industry peers.
With a Return On Invested Capital value of 1.05%, RGEN perfoms like the industry average, outperforming 59.65% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 13.99%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN has a Profit Margin of 0.25%. This is in the better half of the industry: RGEN outperforms 68.42% of its industry peers.
Looking at the Operating Margin, with a value of 6.58%, RGEN is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
In the last couple of years the Operating Margin of RGEN has declined.
RGEN has a Gross Margin of 51.59%. This is comparable to the rest of the industry: RGEN outperforms 59.65% of its industry peers.
RGEN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so RGEN is destroying value.
Compared to 1 year ago, RGEN has more shares outstanding
RGEN has more shares outstanding than it did 5 years ago.
RGEN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.58 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN's Altman-Z score of 7.58 is amongst the best of the industry. RGEN outperforms 85.96% of its industry peers.
RGEN has a debt to FCF ratio of 5.05. This is a neutral value as RGEN would need 5.05 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 5.05, RGEN is doing good in the industry, outperforming 68.42% of the companies in the same industry.
RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
RGEN has a Debt to Equity ratio (0.26) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.58 |
ROIC/WACC0.1
WACC10.48%
2.3 Liquidity
RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RGEN (8.36) is better than 91.23% of its industry peers.
RGEN has a Quick Ratio of 7.14. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of RGEN (7.14) is better than 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.17%, which is quite impressive.
The Earnings Per Share has been growing slightly by 7.11% on average over the past years.
RGEN shows a decrease in Revenue. In the last year, the revenue decreased by -8.54%.
The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
Based on estimates for the next years, RGEN will show a very strong growth in Earnings Per Share. The EPS will grow by 25.53% on average per year.
RGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.90% yearly.
EPS Next Y14.84%
EPS Next 2Y19.3%
EPS Next 3Y22.48%
EPS Next 5Y25.53%
Revenue Next Year15.58%
Revenue Next 2Y14%
Revenue Next 3Y14.31%
Revenue Next 5Y15.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 100.13, which means the current valuation is very expensive for RGEN.
Compared to the rest of the industry, the Price/Earnings ratio of RGEN is on the same level as its industry peers.
The average S&P500 Price/Earnings ratio is at 26.92. RGEN is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 78.91, the valuation of RGEN can be described as expensive.
RGEN's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 23.46. RGEN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 100.13 | ||
| Fwd PE | 78.91 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RGEN is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 87.87 | ||
| EV/EBITDA | 82.41 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 22.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.75
PEG (5Y)14.09
EPS Next 2Y19.3%
EPS Next 3Y22.48%
5. Dividend
5.1 Amount
No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
166.21
+0.55 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners110.01%
Inst Owner Change16.45%
Ins Owners0.45%
Ins Owner Change-2.87%
Market Cap9.36B
Revenue(TTM)707.89M
Net Income(TTM)1.74M
Analysts81.43
Price Target193.06 (16.15%)
Short Float %8.21%
Short Ratio4.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.48%
Min EPS beat(2)-6.83%
Max EPS beat(2)7.78%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-6.83%
Max EPS beat(4)10.73%
EPS beat(8)4
Avg EPS beat(8)4.05%
EPS beat(12)8
Avg EPS beat(12)8.34%
EPS beat(16)12
Avg EPS beat(16)11.45%
Revenue beat(2)2
Avg Revenue beat(2)2.11%
Min Revenue beat(2)2.07%
Max Revenue beat(2)2.15%
Revenue beat(4)3
Avg Revenue beat(4)0.86%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)2.15%
Revenue beat(8)3
Avg Revenue beat(8)-0.3%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)7
Avg Revenue beat(16)0.58%
PT rev (1m)0.98%
PT rev (3m)5.47%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)-12.15%
EPS NY rev (1m)-0.18%
EPS NY rev (3m)-0.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.04%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)0.9%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 100.13 | ||
| Fwd PE | 78.91 | ||
| P/S | 13.22 | ||
| P/FCF | 87.87 | ||
| P/OCF | 71.48 | ||
| P/B | 4.49 | ||
| P/tB | 16.27 | ||
| EV/EBITDA | 82.41 |
EPS(TTM)1.66
EY1%
EPS(NY)2.11
Fwd EY1.27%
FCF(TTM)1.89
FCFY1.14%
OCF(TTM)2.33
OCFY1.4%
SpS12.58
BVpS37.01
TBVpS10.21
PEG (NY)6.75
PEG (5Y)14.09
Graham Number37.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROCE | 1.67% | ||
| ROIC | 1.05% | ||
| ROICexc | 1.43% | ||
| ROICexgc | 5.46% | ||
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% | ||
| FCFM | 15.04% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexgc growth 3Y-71.22%
ROICexgc growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Debt/EBITDA | 4.85 | ||
| Cap/Depr | 37.9% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 117.95% | ||
| Profit Quality | 6126.58% | ||
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 | ||
| Altman-Z | 7.58 |
F-Score6
WACC10.48%
ROIC/WACC0.1
Cap/Depr(3y)91.1%
Cap/Depr(5y)111.21%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
EPS Next Y14.84%
EPS Next 2Y19.3%
EPS Next 3Y22.48%
EPS Next 5Y25.53%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
Revenue Next Year15.58%
Revenue Next 2Y14%
Revenue Next 3Y14.31%
Revenue Next 5Y15.9%
EBIT growth 1Y163.23%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year69.07%
EBIT Next 3Y37.03%
EBIT Next 5Y36%
FCF growth 1Y9.1%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-10.84%
OCF growth 3Y13.8%
OCF growth 5Y21.15%
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status of REPLIGEN CORP (RGEN) stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the valuation of REPLIGEN CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for REPLIGEN CORP (RGEN) is 100.13 and the Price/Book (PB) ratio is 4.49.
Can you provide the expected EPS growth for RGEN stock?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.